Literature DB >> 33467912

The potential association between PARP14 and the SARS-CoV-2 infection (COVID-19).

Amanda L Tauber1, Stephanie S Schweiker1, Stephan M Levonis1.   

Abstract

Understanding the potential association between the poly (ADP-ribose) polymerase member 14 (PARP14) and the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may aid in understanding the host immunopathological response to the virus. PARP14 has an emerging role in viral infections, and this article considers its potential mechanisms for action in either a pro- or anti-viral manner. It is evident that more experimental work is required; however, PARP14 appears vital in controlling the interferon response to the SARS-CoV-2 infection and has potential roles in balancing the proinflammatory cytokines of the cytokine storm. Furthermore, the SARS-CoV-2 macrodomain can prevent the PARP14-mediated antiviral response, suggesting a more complex relationship between PARP14 activity and SARS-CoV-2 infections.

Entities:  

Keywords:  ARTD8; COVID-19; PARP14; SARS-CoV-2; coronavirus; immunity; viral

Year:  2021        PMID: 33467912     DOI: 10.4155/fmc-2020-0226

Source DB:  PubMed          Journal:  Future Med Chem        ISSN: 1756-8919            Impact factor:   3.808


  18 in total

1.  PARP14 Controls the Nuclear Accumulation of a Subset of Type I IFN-Inducible Proteins.

Authors:  Greta Caprara; Elena Prosperini; Viviana Piccolo; Gianluca Sigismondo; Alessia Melacarne; Alessandro Cuomo; Mark Boothby; Maria Rescigno; Tiziana Bonaldi; Gioacchino Natoli
Journal:  J Immunol       Date:  2018-03-02       Impact factor: 5.422

2.  Design, synthesis and evaluation of potent and selective inhibitors of mono-(ADP-ribosyl)transferases PARP10 and PARP14.

Authors:  Jacob Holechek; Robert Lease; Ann-Gerd Thorsell; Tobias Karlberg; Caitlin McCadden; Ryan Grant; Abby Keen; Evan Callahan; Herwig Schüler; Dana Ferraris
Journal:  Bioorg Med Chem Lett       Date:  2018-05-03       Impact factor: 2.823

3.  Discovery of a novel allosteric inhibitor scaffold for polyadenosine-diphosphate-ribose polymerase 14 (PARP14) macrodomain 2.

Authors:  Moses Moustakim; Kerstin Riedel; Marion Schuller; Andrè P Gehring; Octovia P Monteiro; Sarah P Martin; Oleg Fedorov; Jag Heer; Darren J Dixon; Jonathan M Elkins; Stefan Knapp; Franz Bracher; Paul E Brennan
Journal:  Bioorg Med Chem       Date:  2018-03-12       Impact factor: 3.641

4.  Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.

Authors:  Justin Stebbing; Venkatesh Krishnan; Anabela Cardoso; Mario Corbellino; Stephanie de Bono; Silvia Ottaviani; Giacomo Casalini; Peter J Richardson; Vanessa Monteil; Volker M Lauschke; Ali Mirazimi; Sonia Youhanna; Yee-Joo Tan; Fausto Baldanti; Antonella Sarasini; Jorge A Ross Terres; Brian J Nickoloff; Richard E Higgs; Guilherme Rocha; Nicole L Byers; Douglas E Schlichting; Ajay Nirula
Journal:  EMBO Mol Med       Date:  2020-06-24       Impact factor: 12.137

Review 5.  SARS-CoV-2 and COVID-19: Is interleukin-6 (IL-6) the 'culprit lesion' of ARDS onset? What is there besides Tocilizumab? SGP130Fc.

Authors:  Giuseppe Magro
Journal:  Cytokine X       Date:  2020-05-14

6.  The coronavirus macrodomain is required to prevent PARP-mediated inhibition of virus replication and enhancement of IFN expression.

Authors:  Matthew E Grunewald; Yating Chen; Chad Kuny; Takashi Maejima; Robert Lease; Dana Ferraris; Masanori Aikawa; Christopher S Sullivan; Stanley Perlman; Anthony R Fehr
Journal:  PLoS Pathog       Date:  2019-05-16       Impact factor: 6.823

Review 7.  Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy.

Authors:  Peter M George; Athol U Wells; R Gisli Jenkins
Journal:  Lancet Respir Med       Date:  2020-05-15       Impact factor: 30.700

8.  COVID-19: consider cytokine storm syndromes and immunosuppression.

Authors:  Puja Mehta; Daniel F McAuley; Michael Brown; Emilie Sanchez; Rachel S Tattersall; Jessica J Manson
Journal:  Lancet       Date:  2020-03-16       Impact factor: 79.321

9.  Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19.

Authors:  Abinit Saha; Ashish Ranjan Sharma; Manojit Bhattacharya; Garima Sharma; Sang-Soo Lee; Chiranjib Chakraborty
Journal:  Arch Med Res       Date:  2020-05-21       Impact factor: 2.235

Review 10.  Nervous system involvement after infection with COVID-19 and other coronaviruses.

Authors:  Yeshun Wu; Xiaolin Xu; Zijun Chen; Jiahao Duan; Kenji Hashimoto; Ling Yang; Cunming Liu; Chun Yang
Journal:  Brain Behav Immun       Date:  2020-03-30       Impact factor: 7.217

View more
  3 in total

1.  N,N'-Diphenyldithiomalonodiamide: Structural Features, Acidic Properties, and In Silico Estimation of Biological Activity.

Authors:  A E Sinotsko; A V Bespalov; N V Pashchevskaya; V V Dotsenko; N A Aksenov; I V Aksenova
Journal:  Russ J Gen Chem       Date:  2021-12-17       Impact factor: 0.868

2.  Can molecular mimicry explain the cytokine storm of SARS-CoV-2?: An in silico approach.

Authors:  Gustavo Obando-Pereda
Journal:  J Med Virol       Date:  2021-06-11       Impact factor: 20.693

Review 3.  Functional roles of ADP-ribosylation writers, readers and erasers.

Authors:  Ping Li; Yushuang Lei; Jia Qi; Wanqin Liu; Kai Yao
Journal:  Front Cell Dev Biol       Date:  2022-08-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.